TheraCryf PLC
8EV
Company Profile
Business description
TheraCryf PLC is a clinical-stage biotechnology company focused on profitable segments in oncology and neuropsychiatry. The company's lead clinical asset, SFX-01 is a patented form of delivering sulforaphane, which could be used in the treatment of a number of cancers, neurodevelopmental disorders, and other diseases.
Contact
Congleton Road
Alderley Park
Nether AlderleyCheshireSK10 4TG
GBRT: +44 1625315090
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 March 2026
Employees
9
Stocks News & Analysis
stocks
Apple: Gemini partnership lets AI-worried investors breathe a sigh of relief
We believe a competitive—if not leading—AI feature suite will reinforce Apple’s wide-moat mobile device ecosystem.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,184.20 | 27.30 | -0.30% |
| CAC 40 | 8,310.84 | 20.12 | -0.24% |
| DAX 40 | 25,300.83 | 14.59 | 0.06% |
| Dow JONES (US) | 49,390.79 | 241.16 | 0.49% |
| FTSE 100 | 10,244.14 | 59.79 | 0.59% |
| HKSE | 26,923.62 | 76.19 | -0.28% |
| NASDAQ | 23,647.37 | 175.62 | 0.75% |
| Nikkei 225 | 54,110.50 | 230.73 | -0.42% |
| NZX 50 Index | 13,659.79 | 97.92 | -0.71% |
| S&P 500 | 6,963.12 | 36.52 | 0.53% |
| S&P/ASX 200 | 8,861.70 | 19.30 | -0.22% |
| SSE Composite Index | 4,112.60 | 13.49 | -0.33% |